Synthetic cannabinoids further rift between marijuana and hemp industries

A recent ruling from the U.S. Drug Enforcement Administration classifying a synthetic cannabinoid as a Schedule 1 drug has furthered the ire between the licensed cannabis industry and the largely unregulated cannabinoid sector, which has grown into a multi-billion market amid the proliferation of CBD and Delta-lineage products since the passage of the 2018 Farm Bill.

Chart showing cannabinoid market breakdown

Cannabis entrepreneurs partner with Bubba Kush creator to offer unique genetics

As former general manager of three Arena Football League teams, Reggie Harris knows the importance of going on offense.

So, in 2021, when Harris and his team launched House of Kush, a Kansas City, Missouri-based company that sells cannabis-plant genetics via seedlings and licensing deals, he didn’t wait for clients to come find him.